

MAY 2025

Date	Headline and Source	Link	Summary
2 nd May	India's First Dengue Vaccine Qdenga Set For 2026 Launch Guwahati Plus, May 02, 2025	India's First Dengue Vaccine Qdenga Set For 2026 Launch	India's first dengue vaccine, Qdenga, is expected to be launched in 2026 through a collaboration between Japanese pharmaceutical company Takeda and Hyderabad-based Biological E (Bio E). The vaccine, also known as TAK-003, is part of Takeda's global push against dengue and aligns with India's 'Make in India' initiative.
4 th May	CDSCO Panel Approves Novartis Healthcare's Protocol Amendment to study Iptacopan Medical Dialogues, May 04, 2025	CDSCO Panel Approves Novartis Healthcare's Protocol Amendment to study Iptacopan	The Subject Expert Committee (SEC), functional under the Central Drug Standard Control Organization (CDSCO), has approved the protocol amendment proposal presented by Novartis Healthcare for Iptacopan (LNP023) study.
4 th May	Merck launches two-minute self-check campaign to curb oral cancer rise across India Media Brief, May 04, 2025	Merck launches two-minute self-check campaign to curb oral cancer rise across India	In a nationwide push for cancer awareness, Merck Specialities, in collaboration with leading hospitals across India, has launched the Two-Minute Action for Oral Cancer Protection campaign under the banner #ActAgainstOralCancer.
4 th May	India is the Obvious Place to Find Skills and Scale, Says Novo Nordisk GBS MD on Building GCCs Analytics India Mag, May 04, 2025	India is the Obvious Place to Find Skills and Scale, Says Novo Nordisk GBS MD on Building GCCs	Some Nordic firms such as Volvo Group, Novo Nordisk, Nokia, KONE, and IKEA have already set up GCCs in India due to its deep expertise in IT, artificial intelligence (AI), analytics, and engineering. Moreover, with potential cost savings of up to 70%, the country offers a compelling offshoring proposition.
5 th May	CDSCO Panel Approves AstraZeneca's Protocol Amendment for Anticancer Drug AZD0901 study Medical Dialogues, May 05, 2025	CDSCO Panel Approves AstraZeneca's Protocol Amendment for Anticancer Drug AZD0901 study	The Subject Expert Committee (SEC), functional under the Central Drug Standard Control Organisation (CDSCO), has approved AstraZeneca Pharma India's proposal for protocol amendment of the clinical trial of AZD0901 powder for solution for infusion.
5 th May	Johnson and Johnson Gets CDSCO Panel nod for Additional Indication of Ustekinumab solution for injection Medical Dialogues, May 05, 2025	Johnson and Johnson Gets CDSCO Panel nod for Additional Indication of Ustekinumab solution for injection	The Subject Expert Committee (SEC), functional under the Central Drug Standard Control Organization (CDSCO), has granted approval to Johnson and Johnson for the proposed additional indication of Ustekinumab solution for injection 45 mg and 90 mg.
6 th May	OPPI's Matai on India's IPR Regime: Progress, Pain Points, Possibilities	OPPI's Matai on India's IPR Regime: Progress, Pain Points, Possibilities	Anil Matai, director general, Organization of Pharmaceutical Producers of India, discusses the evolving intellectual

	Possibilities Scrip Podcast, May 05, 2025		property landscape in India post the 2024 amendments and long-standing sticking points including Section 3(d) of India's patent regulations and regulatory data protection. Big pharma's experience when it comes to the Bolar provision and the impact of geopolitical shifts on innovation were some of the other topics he touched on.
6 th May	CDSCO Panel approves Eli Lilly proposal to Increase patients number from India 37 to 57 for LY3871801 study Medical Dialogues, May 06, 2025	CDSCO Panel approves Eli Lilly proposal to Increase patients number from India 37 to 57 for LY3871801 study	The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved pharmaceutical major Eli Lilly's proposal to increase the number of patients from India from 37 to 57 for phase 2a part of the study of ant rheumatoid drug LY3871801.
6 th May	Sanofi Healthcare India Gets CDSCO Panel Nod To study SAR441566 Medical Dialogues, May 06, 2025	Sanofi Healthcare India Gets CDSCO Panel Nod To study SAR441566	Sanofi-Healthcare India has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the trial of the drug SAR441566. This came after the firm presented phase II clinical study protocol no. DRI17822 Amendment number 01 Version 01 Dated 19 Dec 2024.
7 th May	Dr. Reddy's partners with Sanofi Healthcare Punya Nagari, May 07, 2025	Dr. Reddy's partners with Sanofi Healthcare	Dr. Reddy's Laboratories Limited has expanded its strategic partnership with Sanofi Healthcare India Private Limited and is set to introduce a new drug, Beyfortus (Nirsevimab), in India. Under this agreement, Dr. Reddy's has received exclusive rights for the promotion and distribution of Beyfortus (Nirsevimab) in India.
8 th May	RGCIRC launches campaign for early oral cancer detection ET Health World, May 08, 2025	RGCIRC launches campaign for early oral cancer detection	Rajiv Gandhi Cancer Institute & Research Centre (RGCIRC), Rohini, New Delhi, in association with Merck Specialities Private Limited has launched the Two-Minute Action for Oral Cancer Protection campaign with the hashtag #ActAgainstOralCancer.
8 th May	Mounjaro is now a heavyweight in weight-loss fight The Economic Times, May 08, 2025	Mounjaro is now a heavyweight in weight-loss fight	Consumption of Mounjaro, Eli Lilly's blockbuster weight-loss drug, more than tripled within a month of its launch in India, according to data from industry tracker and market researcher PharmaTrac. According to the data, sales of Mounjaro 2.5 mg injections surged to 4.8 crore in April from 1.42 crore in March,

			when the drug was launched in the country.
9 th May	Johnson & Johnson Medtech partners with Qure.ai to boost early detection of lung cancer in India BioSpectrum India, May 09, 2025	Johnson & Johnson Medtech partners with Qure.ai to boost early detection of lung cancer in India	Johnson & Johnson MedTech, a global leader in surgical technologies and solutions, has onboarded Qure.ai, a global leader in artificial intelligence (AI) for healthcare, as a strategic partner with Johnson & Johnson Private Limited, a Johnson & Johnson company, to enhance early detection of lung cancer in India. This collaboration brings together cutting-edge AI and medical technology, helping identify lung cancer at its most treatable stage.
9 th May	India expands use of AstraZeneca's drug for advanced breast cancer cases India Today, May 09, 2025	India expands use of AstraZeneca's drug for advanced breast cancer cases	AstraZeneca Pharma India has received approval from India's drug regulator to expand the use of a breast cancer treatment that could bring new hope to many women with advanced disease. The medicine, Trastuzumab deruxtecan, was already available for some breast and stomach cancers.
9 th May	Johnson & Johnson Vision plans India-specific innovation pipeline for growing eye care market Business Today, May 09, 2025	Johnson & Johnson Vision plans India-specific innovation pipeline for growing eye care market	American Healthcare giant Johnson & Johnson's eye health arm, J&J Vision is preparing a pipeline of India-specific innovations and clinical trials and is considering expanded localisation and strategic collaborations to meet the country's rising demand for advanced eye care, Christoph Vonwiller, President, Vision, AsiaPacific at Johnson & Johnson Vision told Business Today.
18 th May	Natura Non Facit Saltum: Incremental Innovation in Pharmaceuticals ET Pharma, May 18, 2025	Natura Non Facit Saltum: Incremental Innovation in Pharmaceuticals	With the Indian government placing greater emphasis on research, innovation, and the development of a robust pharmaceutical ecosystem, the time is ripe for reform. As an organisation representing R&D-driven pharmaceutical companies, Organisation of Pharmaceutical Producers of India (OPPI) advocates for a balanced interpretation of Section 3(d).
18 th May	Pfizer Gets CDSCO Panel Nod To study Anticancer Drug Disitamab vedotin Medical Dialogues, May 18, 2025	Pfizer Gets CDSCO Panel Nod To study Anticancer Drug Disitamab vedotin	Pfizer has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the trial of the anticancer drug Disitamab vedotin. However, this approval is subject to the condition to include more geographically distributed government sites in the study

			and the principal investigator (PI) should be a medical oncologist.
18 th May	CDSCO panel Approves AstraZeneca Pharma India's Protocol Amendment proposal to study Durvalumab-Tremelimumab Medical Dialogues, May 18, 2025	CDSCO panel Approves AstraZeneca Pharma India's Protocol Amendment proposal to study Durvalumab-Tremelimumab	The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved AstraZeneca Pharma India's proposal for the protocol amendment of the clinical trial titled A Randomized, Openlabel, Multicenter Phase III Study of Durvalumab and Tremelimumab as Firstline Treatment in Patients with Advanced Hepatocellular Carcinoma.
18 th May	Mirror check drive to curb oral cancer The Times of India, May 18, 2025	Mirror check drive to curb oral cancer	This information was shared during a programme to launch a nationwide Two-Minute Action for Oral Cancer Protection campaign by Medanta Hospital and Merck Specialities Private Limited. Recently Oral cancer, part of the broader category of head and neck cancers, often goes unnoticed until advanced stages.
21 st May	AstraZeneca Pharma India gets CDSCO Panel nod for Anticancer Drug Osimertinib Tablets 40 mg and 80 mg Medical Dialogues, May 21, 2025	AstraZeneca Pharma India gets CDSCO Panel nod for Anticancer Drug Osimertinib Tablets 40 mg and 80 mg	With the condition of conducting a Phase IV clinical trial study, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has granted approval to AstraZeneca Pharma India to import and market Osimertinib tablets 40mg and 80 mg for the proposed additional indication.
22 nd May	CDSCO Panel Recommends Protocol Amendment for Novartis lanalumab Trial Medical Dialogues, May 22, 2025	CDSCO Panel Recommends Protocol Amendment for Novartis lanalumab Trial	The matter was taken up during the 4th SEC (Haematology) meeting of 2025 held on April 8 at CDSCO headquarters, New Delhi. According to the official minutes, The firm presented protocol amendment version 05 dated 27 January 2025 protocol no. CVAY736I12301. After detailed deliberation, the committee recommended for approval of protocol amendment as presented by the firm.
22 nd May	Eli Lilly Gets CDSCO Panel Nod To import, and market anticancer Selpercatinib Tablets Medical Dialogues, May 22, 2025	Eli Lilly Gets CDSCO Panel Nod To import, and market anticancer Selpercatinib Tablets	Pharmaceutical major Eli Lilly has got a goahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) to import and market the anticancer drug Selpercatinib Tablets 40mg, 80mg, 120mg and 160mg for proposed strength and indication with the condition to conduct Phase IV clinical trials.
22 nd May	Pfizer, GITAM University Empower Rural Women with	Pfizer, GITAM University Empower Rural Women with	To increase women representation in the pharmaceutical industry, Pfizer Global

	Employment through Pfizer Autonomous Teams Program Deccan Chronicle, May 22, 2025	Employment through Pfizer Autonomous Teams Program	Supply's manufacturing unit in Visakhapatnam has partnered with Gandhi Institute of Technology and Management (GITAM) University, Visakhapatnam.
23 rd May	New GCCs set up and existing GCCs expansion in India – An overview Community Nasscom, May 23, 2025	New GCCs set up and existing GCCs expansion in India – An overview	With respect to the expansion of centres, 23 new centres were established by existing GCCs. Some of the notable names include Pernod Ricard, Bristol Myers Squibb, DE Shaw and Co, Harman, Deloitte, among others. Expansion of centres of established GCCs in India in H1 CY2023
23 rd May	Novo Nordisk Foundation pledges \$57 million to WHO amid US funding gap CNBC TV18, May 23, 2025	Novo Nordisk Foundation pledges \$57 million to WHO amid US funding gap	The Novo Nordisk Foundation has pledged up to DKK 380 million (\$57.76 million) to the World Health Organisation (WHO) to expand its tieup with the United Nations agency for another four years, the philanthropic body said on Wednesday WHO.
23 rd May	Novo Nordisk Foundation enters into strategic framework agreement with WHO to advance global health Biospectrumasia, May 23, 2025	Novo Nordisk Foundation enters into strategic framework agreement with WHO to advance global health	Novo Nordisk Foundation has entered into strategic framework agreement with the World Health Organization (WHO) to advance global health. With the agreement, the Foundation expands its existing collaboration with WHO, committing to a granting frame of up to DKK 380 million over the next four years.
25 th May	Sanofi Gets CDSCO Panel Nod to Update Aldurazyme Prescribing Information Medical Dialogues, May 25, 2025	Sanofi Gets CDSCO Panel Nod to Update Aldurazyme Prescribing Information	This approval follows Sanofi's submission seeking alignment of the Indian prescribing information with the US Prescribing Information (USPI) dated December 2023. Aldurazyme, which contains the active ingredient laronidase, is used for enzyme replacement therapy in patients with Mucopolysaccharidosis I (MPS I), a rare inherited disorder.
26 th May	CDSCO Panel Approves Fabrazyme Label Update, Asks Sanofi to Submit EMA Nod Medical Dialogues, May 26, 2025	CDSCO Panel Approves Fabrazyme Label Update, Asks Sanofi to Submit EMA Nod	The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has granted approval to Sanofi Healthcare India Pvt. Ltd. to update the prescribing information for Fabrazyme (Agalsidase Beta Powder for Concentrate for Solution for Infusion, 35 mg and 5 mg) in line with the company's global core safety data.
27 th May			
28 th May	Goa's AI-Driven Lung Cancer Screening Program Shows Promising Results Goemkarponn, May 28, 2025	Goa's AI-Driven Lung Cancer Screening Program Shows Promising Results	In a landmark step toward transforming healthcare through early disease detection, the state of Goa has successfully conducted 56,752 lung

			cancer screening scans, resulting in the identification of 5,498 nodules and 388 high-risk lung nodule malignancies (LNMs). This initiative, powered by advanced AI technology developed by AstraZeneca, spans 19 active screening sites across the state.
30 th May	AstraZeneca gets CDSCO nod for lung cancer drug The Hindu Business Line, May 30, 2025	AstraZeneca gets CDSCO nod for lung cancer drug	AstraZeneca India Pharma on Thursday said it has received approval from the government authority for the import, sale, and distribution of a medication used in treating non-small cell lung cancer. The company has received approval from the Central Drugs Standard Control Organisation (CDSCO), for Osimertinib tablets in strength of 40mg and 80mg, AstraZeneca India said in a statement.
30 th May	Eli Lilly Apollo join hands to raise awareness about obesity type 2 diabetes The Week, May 30, 2025	Eli Lilly Apollo join hands to raise awareness about obesity type 2 diabetes	Eli Lilly and Company (India) on Thursday said it has inked a pact with Apollo Group to raise awareness about obesity and type 2 diabetes. The company has entered into a partnership with Apollo Clinic, a clinic network under Apollo Health and Lifestyle, and Apollo HealthCo (Apollo 24 7), all part of the larger Apollo Group.
